Drug Profile
EPI 12322
Latest Information Update: 09 Jul 2013
Price :
$50
*
At a glance
- Originator EpiGenesis Pharmaceuticals
- Class Antiasthmatics
- Mechanism of Action Adenosine deaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 09 Jul 2013 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 30 Aug 2002 No development reported - Preclinical for Asthma in USA (unspecified route)
- 27 Jul 1999 Preclinical development for Asthma in USA (Unknown route)